Artgen Ventures, a subsidiary of Artgen Biotech (MOEX: ABIO), will buy back shares from investors of Biotechnology Development (RBT) under the terms of an offer, according to which the buyback will be made from investors who invested RUB 1 million or more and retained ownership of the shares from the time of their acquisition.
The decision was made at the meeting of the Board of Directors of Artgen Biotech on March 10, 2026.
Investors will be able to exercise their rights during the period from April 20 to May 20, 2026.
In 2023, RBT conducted a private placement of shares on the Rounds investment platform, raising RUB 155 million. As part of the placement, investors were provided with an offer, under the terms of which Artgen Ventures undertook to buy back shares acquired through the private subscription in 2026 at the investment price.
RBT is a resident of Skolkovo and MedTech Technopark. RBT shares are available for trading on the Over-The-Counter (OTC) market of the Moscow Exchange. Ticker: RBTY.
According to the Company's strategy, updated in November 2025, the vaccine segment remains a priority for RBT, as it is in this area that the Company possesses key competencies. RBT's portfolio includes three vaccines at an advanced stage of development: TetraFluBet (influenza), Betuvax-Cov-2 (coronavirus), and a combined coronavirus and influenza vaccine. The Company is focused on the further development of these vaccines and will seek partners to continue their development under a licensing model.
RBT will focus on developing new vaccines whose antigens will be wholly owned by the Company without supplies from third-party partners. In 2025, RBT launched the development of a vaccine against respiratory syncytial virus (RSV). The Company also plans to develop a line of animal vaccines. This segment features a simpler regulatory pathway and will allow the Company to generate revenue more quickly.
RBT plans to provide contract manufacturing services for medical devices at its pilot production facility in the Perm Region.
In 2025, RBT began developing: an organ preservation solution (a medical device), a cancer vaccine for companion animals, and an adjuvant for veterinary vaccines.
In 2025, VISUS LAB successfully completed the development and registration of the innovative eyelid hygiene gel "Blepharosept" as a cosmetic product. The product contains RBT's innovative form of betulin, "Betusphere". "Blepharosept" is currently being prepared for launch into retail chains.